Clinical trial
A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With…
NCT00001587 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00001587 |
|---|---|
| Title | A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver |
| Official title | A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Liver Neoplasms, Neoplasm Metastasis |
| Intervention type | Drug, Procedure |
| Interventions | Isolated hepatic portal and arterial perfusion, Melphalan |
| Enrollment | 30 |
| Start date | Sep 1, 1997 |
| Completion | Mar 1, 2001 |
| First posted | Dec 10, 2002 |
| Last update posted | Mar 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: